IL6 and chronic kidney disease: In the IL-6 Inhibition with Ziltivekimab in Patients at High Atherosclerotic Risk (RESCUE) study, patients with advanced CKD and elevated hsCRP levels were treated monthly with ziltivekimab, a fully human monoclonal antibody directed against the IL-6 ligand, and results showed that multiple atherosclerosis-related inflammatory biomarkers were significantly suppressed [65].